Mini tumors in a dish could personalize bladder cancer treatment

NCT ID NCT07379281

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a new way to choose chemotherapy for muscle-invasive bladder cancer. Doctors will grow a miniature version of a patient's tumor in the lab (called an organoid) and test different drugs on it to see which works best. Then, the patient receives the drug that killed their organoid. The study compares survival rates of patients who get this personalized approach versus those who get standard chemotherapy, aiming to see if organoid-guided treatment leads to better outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

organoid drug sensitivity testing

What this could lead to

If successful, this approach could personalize chemotherapy for bladder cancer, potentially improving survival rates by selecting the most effective drugs for each patient.

What could go wrong

This is a relatively early-stage study (254 participants) comparing a new testing method to standard care. The organoid test may not accurately predict real drug response, and results may not apply to all patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infiltrating bladder urothelial carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Qilu Hospital of Shandong University

    RECRUITING

    Jinan, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••